Fundraising Fox3E Bioventures Capital — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases.
BiotechDeep TechMedical DevicesHayward, US
Haifeng Chen(Director and Treasurer of the Issuer)inShengjiang Liu(Executive Officer, Director)
BoardYu Fang(Director of the Issuer)Qianye Karen Liu(Director of the Issuer)Nancy Chang(Director of the Issuer)
Co-investorsBioVentures
Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit.
BiotechHealthtechSan Diego, US
James Mackay(Co-Founder)David Bullough(Director)Daniel Petree(Director)J. Gordon Foulkes(Executive Officer, Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.